News | February 24, 2026
Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies
Under the deal, Quiver will receive an undisclosed advance payment and research support
Under the deal, Quiver will receive an undisclosed advance payment and research support
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Subscribe To Our Newsletter & Stay Updated
